BDSX Biodesix

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.

Canaccord Genuity 45th Annual Growth Conference

Fireside Chat Date: Tuesday, August 12, 2025

Fireside Chat Time: 4:30 PM ET

Location: Boston, MA

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit .

Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.

Contacts:

Media:

Natalie St. Denis



1-720-925-9285

Investors:

Chris Brinzey



1-339-970-2843



EN
05/08/2025

Underlying

BDSXBiodesix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence...

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix ...

August 19, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Second Quarter 2025 Results and Highlights

Biodesix Announces Second Quarter 2025 Results and Highlights Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. “We had strong second qu...

August 7, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Confer...

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. Canaccord Genuity 45th Annual Growth Conference Fireside Chat Date: Tuesday, August 12, 2025Fireside Chat Time: 4:30 PM ETLocation: Boston, MA The presentation wi...

August 5, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Report Second Quarter 2025 Financial Results on August 7, ...

Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Analysts who wish to participate in t...

July 24, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Partners with Association of Pulmonary Advanced Practice Prov...

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational pr...

June 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch